-
February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers
Please join us on R & D Day 8:00 AM - Targeting Ferroptosis to Iron Out Resistant CancersFebruary 22, 2022
Loading posts...
Recent Posts
- Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
- Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
- In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
- Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
- Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers